Suppr超能文献

miR-223-3p 通过直接靶向 CDH6 抑制人骨肉瘤转移和进展。

miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6.

机构信息

Department of Orthopaedics, General Hospital of Chinese People's Liberation Army, Beijing, China; Department of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.

Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, China.

出版信息

Mol Ther. 2018 May 2;26(5):1299-1312. doi: 10.1016/j.ymthe.2018.03.009. Epub 2018 Mar 14.

Abstract

Cadherin-6 (CDH6) is aberrantly expressed in cancer and closely associated with tumor progression. However, the functions of CDH6 in human osteosarcoma and the molecular mechanisms underlying CDH6 in osteosarcoma oncogenesis remain poorly understood. In this work, we assessed the role of CDH6 in human osteosarcoma and identified that the expression of CDH6 was closely related with the overall survival and poor prognosis of osteosarcoma patients. MicroRNAs (miRNAs) have been implicated as important epigenetic regulators during the progression of osteosarcoma. Using dual-luciferase reporter assays, we showed that miR-223-3p suppresses CDH6 expression by directly binding to the 3' UTR of CDH6. miR-223-3p overexpression significantly inhibited cell invasion, migration, growth, and proliferation by suppressing the CDH6 expression in vivo and in vitro. Besides, CDH6 overexpression in the miR-223-3p-transfected osteosarcoma cells effectively rescued the inhibition of cell invasion, migration, growth, and proliferation mediated by miR-223-3p. Additionally, Kaplan-Meier analysis suggests that the expression of miR-223-3p predicts favorable clinical outcomes for osteosarcoma patients. Moreover, the expression of miR-223-3p was downregulated in osteosarcoma patients and was negatively associated with the expression of CDH6. Collectively, these data highlight that miR-223-3p/CDH6 axis is an important novel pleiotropic regulator and could early predict the metastatic potential in human osteosarcoma treatments.

摘要

钙黏蛋白 6(CDH6)在癌症中异常表达,与肿瘤进展密切相关。然而,CDH6 在人骨肉瘤中的功能以及 CDH6 在骨肉瘤发生中的分子机制仍知之甚少。在这项工作中,我们评估了 CDH6 在人骨肉瘤中的作用,并发现 CDH6 的表达与骨肉瘤患者的总生存率和预后不良密切相关。微小 RNA(miRNA)被认为是骨肉瘤进展过程中重要的表观遗传调控因子。通过双荧光素酶报告基因实验,我们表明 miR-223-3p 通过直接结合 CDH6 的 3'UTR 来抑制 CDH6 的表达。miR-223-3p 过表达通过抑制 CDH6 在体内和体外的表达,显著抑制细胞侵袭、迁移、生长和增殖。此外,在 miR-223-3p 转染的骨肉瘤细胞中过表达 CDH6,可有效挽救 miR-223-3p 介导的细胞侵袭、迁移、生长和增殖的抑制作用。此外,Kaplan-Meier 分析表明,miR-223-3p 的表达可预测骨肉瘤患者的良好临床结局。此外,miR-223-3p 在骨肉瘤患者中的表达下调,并与 CDH6 的表达呈负相关。综上所述,这些数据表明,miR-223-3p/CDH6 轴是一个重要的新型多效调节因子,可早期预测人骨肉瘤治疗中的转移潜能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/5993963/1a7ed73dc2f4/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验